Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , appears to represent a promising step forward for body treatment. Early clinical trials have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide